Pharma IT and AI – 2024 Health IT Predictions

Discussions will focus on the nuanced packaging and delivery requirements for MABs, emphasizing the commitment to safety standards while ensuring the drugs’ effectiveness.
AI/Automation in Pharma and Healthcare
In 2024, the pharmaceutical landscape can expect a continued shift as AI continues to reshape drug development and healthcare practices. Across genomics, proteomics, and patient data, AI algorithms are beginning to decipher vast datasets to discover new drug targets, refine clinical trials, and tailor treatments to individual patients. The application of machine learning and deep learning is enhancing the creation of predictive models, cutting costs, and simplifying the timelines of drug development.
AI’s influence also optimized drug manufacturing processes, enhancing efficiency, and reducing waste. The AI revolution has been and will continue to redefine the pharmaceutical industry in 2024, promising transformative outcomes for patients.
Dave Latshaw, CEO at BioPhy
1. Significant Increase in Big Pharma M&A as Biotech Rebounds
Data-Driven M&A Strategies: In 2024, generative AI is expected to significantly aid in sifting through vast datasets to identify optimal M&A targets in the biotech sector, focusing on companies with innovative pipelines and technologies that align with Big Pharma’s strategic goals.
Streamlining Due Diligence with AI: AI technologies will likely be crucial in conducting efficient and thorough due diligence, examining...

Source: EMR and HIPAA - January 8, 2024 Category: Information Technology Authors: John Lynn Tags: Analytics/Big Data Health IT Company Healthcare IT Regulations 2024 Health IT Predictions Abpro Adhere Health Angie Franks Archana Hedge BioPhy Curavit Clinical Research Dave Latshaw Definitive Healthcare Dr. Kate Sasser Ian Ch Source Type: blogs